A detailed history of Deutsche Bank Ag\ transactions in Bio Atla, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 525,353 shares of BCAB stock, worth $688,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares
525,353
Previous 1,195,353 56.05%
Holding current value
$688,212
Previous $1.64 Million 43.56%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.17 - $2.05 $783,900 - $1.37 Million
-670,000 Reduced 56.05%
525,353 $924,000
Q2 2024

Aug 14, 2024

SELL
$1.37 - $3.92 $66,984 - $191,664
-48,894 Reduced 3.93%
1,195,353 $1.64 Million
Q1 2024

May 15, 2024

BUY
$1.88 - $3.46 $223,802 - $411,892
119,044 Added 10.58%
1,244,247 $4.28 Million
Q4 2023

Feb 14, 2024

BUY
$1.27 - $3.18 $1.07 Million - $2.69 Million
846,081 Added 303.12%
1,125,203 $2.77 Million
Q3 2023

Nov 09, 2023

SELL
$1.7 - $3.07 $702,555 - $1.27 Million
-413,268 Reduced 59.69%
279,122 $474,000
Q1 2023

May 15, 2023

BUY
$2.3 - $8.25 $675,673 - $2.42 Million
293,771 Added 73.7%
692,390 $1.86 Million
Q4 2022

Feb 13, 2023

BUY
$6.29 - $11.01 $629,000 - $1.1 Million
100,000 Added 33.49%
398,619 $3.29 Million
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $441,000 - $1.78 Million
150,000 Added 100.93%
298,619 $2.3 Million
Q2 2022

Aug 11, 2022

SELL
$2.13 - $5.38 $70,157 - $177,206
-32,938 Reduced 18.14%
148,619 $424,000
Q1 2022

May 13, 2022

SELL
$4.38 - $18.78 $4,051 - $17,371
-925 Reduced 0.51%
181,557 $908,000
Q4 2021

Feb 11, 2022

SELL
$19.0 - $30.95 $41,021 - $66,821
-2,159 Reduced 1.17%
182,482 $3.58 Million
Q3 2021

Nov 04, 2021

SELL
$29.44 - $43.74 $5.53 Million - $8.22 Million
-187,970 Reduced 50.45%
184,641 $5.44 Million
Q2 2021

Aug 11, 2021

BUY
$38.07 - $56.17 $13.9 Million - $20.5 Million
364,924 Added 4747.29%
372,611 $15.8 Million
Q1 2021

May 13, 2021

BUY
$32.41 - $70.91 $249,135 - $545,085
7,687 New
7,687 $0

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $47.6M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.